Join to View Full Profile
4940 Eastern AveBaltimore, MD 21224
Phone+1 410-550-5624
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Sanjay Keswani, MD is a neurologist in Baltimore, Maryland.
Education & Training
Johns Hopkins UniversityFellowship, Clinical Neurophysiology, 2001 - 2002- Johns Hopkins UniversityResidency, Neurology, 1998 - 2001
- Johns Hopkins UniversityResidency, Internal Medicine, 1997 - 1998
Publications & Presentations
PubMed
- 8 citationsProof-of-Mechanism Study of the Phosphodiesterase 10 Inhibitor RG7203 in Patients With Schizophrenia and Negative Symptoms.Daniel Umbricht, Markus Abt, Paul Tamburri, Christopher Chatham, Štefan Holiga
Biological Psychiatry Global Open Science. 2021-06-01 - 2 citationsComparison of different QT interval correction methods for heart rate and QT beat-to-beat method in a thorough QT study of triple monoamine reuptake inhibitor BMS-820836.Ming Zheng, David Burt, Wai Chan, Dara Hawthorne, Maciej Gasior
Journal of Clinical Pharmacology. 2015-10-01 - 45 citationsNitric oxide prevents axonal degeneration by inducing HIF-1–dependent expression of erythropoietinSanjay C. Keswani, Marta Bosch-Marce, Nicole Reed, Angela Fischer, Gregg L. Semenza
Proceedings of the National Academy of Sciences of the United States of America. 2011-03-22
Press Mentions
Neurocrine Biosciences Presented One-Year Data from Phase 3 CAHtalyst™ Studies Showing Improvements in Weight-Related Effects of Glucocorticoid Treatment at the 2025 Endocrine Society’s Annual MeetingJuly 15th, 2025- Neurocrine Biosciences Presents New Post-Hoc Data Analyses from KINECT®-HD Study Demonstrating Significant Reduction in Disease Burden with INGREZZA® (Valbenazine) Capsules for Huntington's Disease ChoreaJune 27th, 2025
- Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (Valbenazine) Capsules in Older Adults with Tardive DyskinesiaJune 20th, 2025
- Join now to see all
